IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has announced the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. The release date has been moved from March 13 to March 28, 2025, with an earnings call scheduled for 10:30 AM Eastern Time on the same day.
The delay is attributed to providing additional time for auditors to complete necessary reviews and audit requirements, specifically focusing on valuation calculations of goodwill and intangible assets. This extension aims to ensure accurate financial data representation and full regulatory compliance.
ImmunoPrecise Antibodies (NASDAQ: IPA), un'azienda di scoperta e sviluppo di anticorpi potenziata dall'IA, ha annunciato il riprogrammazione della pubblicazione dei risultati finanziari e dei punti salienti aziendali del Terzo Trimestre Fiscale 2025. La data di rilascio è stata spostata dal 13 marzo al 28 marzo 2025, con una chiamata sugli utili programmata per le 10:30 AM ora orientale dello stesso giorno.
Il ritardo è attribuito alla necessità di fornire ulteriore tempo agli auditor per completare le revisioni e i requisiti di audit necessari, concentrandosi specificamente sui calcoli di valutazione del goodwill e delle attività immateriali. Questa estensione ha lo scopo di garantire una rappresentazione accurata dei dati finanziari e la piena conformità normativa.
ImmunoPrecise Antibodies (NASDAQ: IPA), una empresa de descubrimiento y desarrollo de anticuerpos impulsada por IA, ha anunciado la reprogramación de la publicación de sus resultados financieros y aspectos destacados comerciales del Tercer Trimestre Fiscal 2025. La fecha de publicación se ha movido del 13 de marzo al 28 de marzo de 2025, con una llamada de ganancias programada para las 10:30 AM hora del Este el mismo día.
El retraso se atribuye a la necesidad de proporcionar tiempo adicional a los auditores para completar las revisiones y los requisitos de auditoría necesarios, centrándose específicamente en los cálculos de valoración de la plusvalía y los activos intangibles. Esta extensión tiene como objetivo garantizar una representación precisa de los datos financieros y el pleno cumplimiento normativo.
ImmunoPrecise Antibodies (NASDAQ: IPA), 인공지능 기반의 항체 발견 및 개발 회사가 2025 회계연도 3분기 재무 결과 및 사업 하이라이트 발표 일정을 변경했다고 발표했습니다. 발표 날짜는 3월 13일에서 2025년 3월 28일로 변경되었으며, 같은 날 동부 표준시 기준 오전 10시 30분에 실적 전화 회의가 예정되어 있습니다.
이번 지연은 감사인들이 필요한 검토 및 감사 요구 사항을 완료할 수 있도록 추가 시간을 제공하기 위한 것으로, 특히 영업권 및 무형 자산의 평가 계산에 중점을 두고 있습니다. 이 연장은 정확한 재무 데이터 표현과 완전한 규제 준수를 보장하기 위한 것입니다.
ImmunoPrecise Antibodies (NASDAQ: IPA), une entreprise de découverte et de développement d'anticorps alimentée par l'IA, a annoncé le report de la publication de ses résultats financiers et des faits saillants commerciaux du Troisième Trimestre Fiscal 2025. La date de publication a été déplacée du 13 mars au 28 mars 2025, avec une conférence téléphonique sur les résultats prévue pour 10h30, heure de l'Est, le même jour.
Le retard est attribué à la nécessité de donner aux auditeurs un temps supplémentaire pour compléter les examens et les exigences d'audit nécessaires, en se concentrant spécifiquement sur les calculs d'évaluation du goodwill et des actifs incorporels. Cette extension vise à garantir une représentation précise des données financières et une conformité réglementaire complète.
ImmunoPrecise Antibodies (NASDAQ: IPA), ein KI-gestütztes Unternehmen zur Entdeckung und Entwicklung von Antikörpern, hat die Veröffentlichung seiner finanziellen Ergebnisse und geschäftlichen Highlights für das 3. Quartal des Geschäftsjahres 2025 neu terminiert. Das Veröffentlichungsdatum wurde vom 13. März auf den 28. März 2025 verschoben, mit einer Telefonkonferenz zu den Ergebnissen, die am selben Tag um 10:30 Uhr Eastern Time angesetzt ist.
Die Verzögerung wird darauf zurückgeführt, dass den Prüfern zusätzliche Zeit gegeben wird, um die erforderlichen Überprüfungen und Prüfanforderungen abzuschließen, insbesondere in Bezug auf die Bewertungsberechnungen von Geschäfts- und immateriellen Vermögenswerten. Diese Verlängerung zielt darauf ab, eine genaue Darstellung der Finanzdaten und die vollständige Einhaltung der Vorschriften sicherzustellen.
- None.
- Delayed financial reporting requiring extended audit review of goodwill and intangible assets valuations
The Company to host an earnings conference call via webcast
The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data accurately reflects the Company's value and complies with all regulatory requirements.
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Friday, March 28, 2025, at 10:30AM ET.
The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.
***Participant Dial-In Details***
Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name.
***Webcast Details***
Attendee URL:
https://events.q4inc.com/attendee/849565157
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311018829/en/
Investor Relations
investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
Why did ImmunoPrecise Antibodies (IPA) delay their Q3 2025 earnings release?
When is IPA's rescheduled Q3 2025 earnings call?
What specific financial aspects are IPA's auditors reviewing?
How can investors access IPA's Q3 2025 earnings call?
